Mobile website
Clinical Research
A meta-analysis of cetuximab combined with chemotherapy in the treatment of advanced colorectal cancer
- Article
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
Abstract:
Objective:To evaluate the clinical outcome and adverse reaction induced by cetuximab combined with chemotherapy in the treatment of advanced colorectal cancer. Methods: In PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Abstract Database (CBM) and China National Knowledge Infrastructure Database (CNKI), we searched randomized controlled trials of cetuximab combined with chemotherapy in the treatment of advanced colorectal cancer up to December 2011 and then decided whether the trials met the selection standard and evaluate the quality of these trails. A meta-analysis was performed on the recruited trails. Results: Five reports, including 3 479 advanced colorectal cancer patients, were selected based on our standard. The pooled relative risks (RRs) for overall response rate in all studies were 28.85% in the cetuximab combined with the chemotherapy treatment group and 18.63% in the control chemotherapy group, and the pooled RR \[95% confidence interval (CI)\] was 2.18 (1.24-3.85, P<0.001). The incidence rate of grade 3-4 fatigue was 10.91% in the combined treatment group and 737% in the control group, and the pooled RR (95%CI) was 1.46 (1.19-1.79, P<0.001). The incidence rate of grade 3-4 diarrhea was 20.41% in the combined treatment group and 12.53% in the control group, and the pooled RR (95%CI) was 1.62 (1.37-1.92, P<0.001). Conclusion:Cetuximab combined with chemotherapy obviously elevates the response rate of advanced colorectal cancer patients. However, it also increases the incidence rate of grade 3-4 fatigue and diarrhea.
Keywords:
advanced colorectal cancer ; cetuximab ; randomized controlled trial ; meta analysis
Project Supported:
Project supported by the National Natural Science Foundation of China (No. 30771838)
